In Medical Devices, Hurry Up and Wait
Executive Summary
Medical device and biotech executives can debate which industry segment is getting a colder shoulder from venture capitalists these days, but it's clear that device start-ups are finding it no easier to attract traditional sources of financing than their counterparts in biotech.
You may also be interested in...
GSK Aims To Launch 13 Blockbusters In Five Years
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Need a specific report? 1000+ reports available
Buy Reports